{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T23:18:34Z","timestamp":1790983114360,"version":"4.1.0"},"reference-count":12,"publisher":"BMJ","issue":"8","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2026,8,6]]},"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:p>\n                    Dasatinib-induced cervicofacial oedema is an exceedingly rare adverse event of second-generation tyrosine kinase inhibitor (TKI) therapy. We report a man in his 40s diagnosed with chronic myeloid leukaemia in myeloid blast crisis (\n                    <jats:italic>BCR::ABL1<\/jats:italic>\n                    88% international scale) who developed progressive facial and neck swelling on day 13 of induction chemotherapy with cytarabine, doxorubicin and dasatinib. In the setting of febrile neutropenia (absolute neutrophil count 200\/\u03bcL), the differential diagnosis included deep space infection and drug reaction. CT imaging demonstrated diffuse cervicofacial oedema without abscess. Vancomycin, initially added for suspected facial cellulitis, was discontinued; piperacillin-tazobactam was continued for febrile neutropenia prophylaxis. Intravenous hydrocortisone 100 mg every 8 hours produced marked improvement by day 2. The patient completed induction, achieved remission and later tolerated dasatinib rechallenge at 100 mg daily during consolidation. This case highlights the diagnostic challenge of TKI-associated oedema in neutropenic patients, the effectiveness of corticosteroids and the feasibility of cautious rechallenge.\n                  <\/jats:p>","DOI":"10.1136\/bcr-2026-275506","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T14:00:35Z","timestamp":1787148035000},"page":"e275506","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Dasatinib-induced cervicofacial oedema in chronic myeloid leukaemia blast crisis"],"prefix":"10.1136","volume":"19","author":[{"given":"Maris May P","family":"Ledesma","sequence":"first","affiliation":[{"name":"Philippine General Hospital, Manila, Philippines"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9789-620X","authenticated-orcid":false,"suffix":"Jr","given":"Rene A","family":"Amadore","sequence":"additional","affiliation":[{"name":"Philippine General Hospital, Manila, Philippines"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April Joy K","family":"Ong","sequence":"additional","affiliation":[{"name":"Philippine General Hospital, Manila, Philippines"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Kristine H","family":"Quero-Taggaoa","sequence":"additional","affiliation":[{"name":"Philippine General Hospital, Manila, Philippines"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,8,19]]},"reference":[{"key":"2026081907002861000_19.8.e275506.1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-08-3097"},{"key":"2026081907002861000_19.8.e275506.2","doi-asserted-by":"publisher","DOI":"10.2147\/tcrm.s3425"},{"key":"2026081907002861000_19.8.e275506.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2022.100968"},{"key":"2026081907002861000_19.8.e275506.4","first-page":"157","article-title":"Dasatinib\u2014clinical trials and management of adverse events in imatinib-resistant\/intolerant chronic myeloid leukemia","volume":"3","author":"Conchon","year":"2012","journal-title":"Ther Adv Hematol"},{"key":"2026081907002861000_19.8.e275506.5","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.beha.2016.10.005","article-title":"Management of CML-blast crisis","volume":"29","author":"Hehlmann","year":"2016","journal-title":"Best Pract Res Clin Haematol"},{"key":"2026081907002861000_19.8.e275506.6","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-2-46"},{"key":"2026081907002861000_19.8.e275506.7","first-page":"113","article-title":"An overview of myeloid blast-phase chronic myeloid leukemia","volume":"37","author":"Pamuk","year":"2023","journal-title":"Hematol Oncol Clin North Am"},{"key":"2026081907002861000_19.8.e275506.8","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1177\/10781552221074050","article-title":"Facial Edema Associated with Dasatinib: Case Report with Successful Treatment","volume":"28","author":"Nyckowski","year":"2022","journal-title":"J Oncol Pharm Pract"},{"key":"2026081907002861000_19.8.e275506.9","first-page":"102225","article-title":"Synchronous enteroid adenocarcinoma at the ureteral implantation site after ureterosigmoidostomy","volume":"45","author":"G\u00f3mez Gonz\u00e1lez","year":"2022","journal-title":"Urol Case Rep"},{"key":"2026081907002861000_19.8.e275506.10","doi-asserted-by":"crossref","DOI":"10.1016\/j.anai.2023.08.326","article-title":"A CASE OF TYROSINE KINASE INHIBITOR (DASATINIB)-INDUCED ANGIOEDEMA","volume":"131","author":"Peterson","year":"2023","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2026081907002861000_19.8.e275506.11","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14752"},{"key":"2026081907002861000_19.8.e275506.12","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-071456","article-title":"Fluid retention-associated adverse events in patients treated with BCR::ABL1 inhibitors based on FDA Adverse Event Reporting System (FAERS): a retrospective pharmacovigilance study","volume":"13","author":"Huang","year":"2023","journal-title":"BMJ Open"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2026-275506","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T14:00:37Z","timestamp":1787148037000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2026-275506"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":12,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8,19]]},"published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1136\/bcr-2026-275506"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2026-275506","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]}}}